Mechanisms of GZ17-6.02 resistance
Laurence Booth1, Cameron West2, Daniel Von Hoff3
1Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia.
Objectives:
The drug GZ17-6.02 is undergoing phase I in solid tumor patients (NCT03775525). The present studies initially determined the impact of prolonged exposure of colorectal tumors to GZ17-6.02, and to determine whether GZ17-6.02 enhanced the efficacy of an anti-PD1 antibody. Subsequently, studies defined the evolutionary resistance mechanisms in tumor cells previously exposed to GZ17-6.02.
Methods:
IACUC-approved animal studies were performed. In cell immunoblotting, cell transfections and trypan blue death assays were performed.
Results:
Prolonged exposure of colorectal tumors to GZ17-6.02 enhanced the efficacy of 5-fluorouracil and of an anti-PD1 antibody, significantly prolonging animal survival. Tumor cells previously exposed to GZ17-6.02 in vivo had elevated their expression of ERBB2 and ERBB3, and increased phosphorylation of ERBB1, ERBB3, PDGFRβ, AKT T308, ERK1/2, p70 S6K T389, STAT5 Y694 and c-SRC Y416. The phosphorylation of c-SRC Y527 declined. The efficacy of ERBB receptor inhibitors at killing these resistant tumor cells was unaltered by prior GZ17-6.02 exposure whereas the efficacy of multi-kinase/PDGFRβ inhibitors was significantly reduced. Treatment of colon cancer cells with GZ17-6.02 rapidly reduced the levels of multiple HDAC proteins and altered their subcellular localization. Isolates from resistant tumors expressed less CD95 and FAS-L. HDAC inhibitors enhanced CD95 and FAS-L levels in the resistant cells via activation of NFκB and HDAC inhibitors restored the efficacy of GZ17-6.02 to near control levels.
Conclusions:
Our findings demonstrate that GZ17-6.02 has the potential to be developed as a colon cancer therapeutic and that resistance to the drug can be partially reversed by HDAC inhibitors.
Insights
The drug GZ17-6.02 shows promise for colon cancer treatment, enhancing anti-PD1 antibody efficacy. Resistance mechanisms involving ERBB signaling were identified, and histone deacetylase (HDAC) inhibitors reversed this resistance.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- GZ17-6.02 is an investigational drug in phase I clinical trials for solid tumors.
- Colorectal cancer (CRC) remains a significant health concern, necessitating novel therapeutic strategies.
- Understanding drug resistance mechanisms is crucial for optimizing cancer treatment efficacy.
Purpose of the Study:
- To evaluate the impact of prolonged GZ17-6.02 exposure on colorectal tumors.
- To determine if GZ17-6.02 enhances the efficacy of anti-PD1 antibody therapy.
- To elucidate the mechanisms of acquired resistance to GZ17-6.02 in tumor cells.
Main Methods:
- In vivo animal studies utilizing colorectal tumor models.
- Cellular assays including immunoblotting, transfection, and trypan blue death assays.
- Analysis of signaling pathway activation and protein expression in resistant tumor cells.
Main Results:
- GZ17-6.02 prolonged survival by enhancing 5-fluorouracil and anti-PD1 antibody efficacy.
- Acquired resistance involved upregulation of ERBB2/ERBB3 and altered phosphorylation of key signaling proteins.
- Histone deacetylase (HDAC) inhibition reversed GZ17-6.02 resistance by restoring CD95 and FAS-L levels.
Conclusions:
- GZ17-6.02 demonstrates therapeutic potential for colon cancer.
- Acquired resistance to GZ17-6.02 can be overcome with combination therapy involving HDAC inhibitors.
- Further development of GZ17-6.02, potentially with HDAC inhibitors, is warranted for colon cancer treatment.
Related Concept Videos
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Equivalent Resistance
Resistance
Design Example: Frog Muscle Response
When the switch connecting the RL circuit is closed, a brief muscle contraction is observed. This is because, at a steady state, the inductor acts like a short...
Design Example: Strain Gauge Bridge or Wheatstone Bridge
Ohm's Law
This current-resisting behavior of resistors is governed by Ohm's law, which states that the voltage across a resistor is directly proportional to the current flowing through it.


